Please login to the form below

Not currently logged in
Email:
Password:

haematological cancer

This page shows the latest haematological cancer news and features for those working in and with pharma, biotech and healthcare.

The Harmony Alliance gathers to battle blood cancer

The Harmony Alliance gathers to battle blood cancer. Uses its big data platform to analyse the disease. ... Michel Van Speybroeck, director of data sciences, Janssen, said: “Public and private partners are bringing together their best people, data and

Latest news

  • AbbVie and Roche plan Venclexta combo filings in leukaemia AbbVie and Roche plan Venclexta combo filings in leukaemia

    Meanwhile, AbbVie is also looking at combining Venclexta with its flagship cancer drug, BTK inhibitor Imbruvica (ibrutinib) for haematological cancer, which has already hit the blockbuster mark with sales topping

  • Intriguing data with Juno's new CAR-T therapy Intriguing data with Juno's new CAR-T therapy

    CAR-T developer Juno Therapeutics has reported data suggesting the benefits of this type of cancer immunotherapy could extend long after the treatment is delivered. ... haematological cancer followed by JCAR017 - an infusion of the patient's own white

  • Celgene joins PD-1 race via partnership with BeiGene Celgene joins PD-1 race via partnership with BeiGene

    The deal for the drug - which is in late-stage trials in cancer and has been tested in around 500 patients to date - gives haematological cancer specialist Celgene a bigger pipeline ... It is a great deal for BeiGene because it gives it a fast-track into

  • Takeda's gamble on Ariad pays off with Alunbrig approval Takeda's gamble on Ariad pays off with Alunbrig approval

    After an accelerated review Alunbrig (brigatinib) has been given a green light as a second-line treatment for ALK-positive, non-small cell lung cancer (NSCLC) after first-line therapy with ... Takeda agreed to buy Ariad earlier this year in a $5.2bn deal,

  • Keytruda claims first blood cancer OK from FDA Keytruda claims first blood cancer OK from FDA

    Keytruda claims first blood cancer OK from FDA. Merck &Co wins US approval for its haematological cancer treatment. ... Merck &Co has won FDA clearance for its PD-1 inhibitor Keytruda in classical Hodgkin lymphoma (cHL), the first green light for the

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch September 2016 Deal Watch September 2016

    Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological malignancies. ... Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics